Q2 Presentation 2023

We create value and contribute to improved quality of life in Life Science

2

Sales and EBITDA rolling 12 months by quarter

The Group's net sales LTM (MSEK)

The Group's EBITDA and EBITA (line) LTM (MSEK)

excluding one-time effects

excluding one-time effects

  • 420
  • 320
  • 220

1 120

  • 020
    920
    820
    720
    620

1 331

300

285

239

257

1 229

250

228

216

203

1 111

187

232

200

174

1 046

203

188

1 007

178

956

150

160

167

916

145

885

133

100

50

0

21Q3

21Q4

22Q1

22Q2

22Q3

22Q4

23Q1

23Q2

21Q3

21Q4

22Q1

22Q2

22Q3

22Q4

23Q1

23Q2

3

MedCap | An active investor in Life Science companies

Second Quarter 2023,

Sales by Business Area

Specialty

Pharma

34%

1 331

MSEK

MedTech

66%

Sales by Product Category

Oth Food 2%

(Nutrition...)

15%Pharma

30%

Medical

Devices

16%

Assistive

Technology

37%

Sales by Market

RoW

2%

Europe

24%

Nordic

21%

Sweden

53%

4

MedCap Platforms

Assistive Technology

Diagnostic ECG

Probiotics, Nutrition

Components for

Pharma & CDMO

CDMO and Packaging

medical imaging

Position

Simplifying life for people

Digitalizing work-flow with easy

Partner for contract

Partner for carbon fiber

with special needs

to use ECG

manufacturing

engineering & manufact'ng

•

Prevalence of e.g. Autism,

•

Cardio diagnostics

•

Wellness

•

Medical imaging

Drivers

ADHD, Dementia

•

Hospital digitalization

•

Fitness

•

Mammography

and mobility

•

Independence, accessibility,

and integration

  • Aging population

Markets

• Nordics, Netherlands, UK,

• Nordics, Germany, Europe

• Nordics

• Europe, USA

Global Exports

Exports

MedTech

MedTech

MedTech

MedTech

Developing and marketing specialty pharma in Nordics

  • Pharmaceutical demand in e.g. Infection; Acute care; ADHD; Substance abuse
  • Pharmaceutical shortages
  • Nordics,
    Outlicensing in Europe

Specialty Pharma

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

MedCap AB published this content on 28 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2023 04:36:08 UTC.